Vicore Pharma Holding (VICO.ST) Stock Analysis & AI Equity Report
Vicore Pharma Holding (VICO.ST) overview
Vicore Pharma Holding (VICO.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Vicore Pharma Holding reported revenue of SEK 3.8m and operating profit of SEK -454m; the year-end share price was 11.30 SEK and market capitalisation was SEK 2,711m. Vicore Pharma Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vicore Pharma Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Vicore Pharma Holding
Vicore Pharma Holding AB (publ) is a clinical-stage biopharmaceutical company developing treatments for respiratory and fibrotic diseases, with a focus on idiopathic pulmonary fibrosis. Its lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist being studied in late-stage clinical trials. The company also advances additional ATRAG-based assets and related pipeline programs.
Generate the Vicore Pharma Holding report
Vicore Pharma Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Vicore Pharma Holding and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.